Strategic Wealth Partners Ltd. Sells 3,220 Shares of GSK plc (NYSE:GSK)

Strategic Wealth Partners Ltd. lessened its stake in shares of GSK plc (NYSE:GSK) by 27.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 8,569 shares of the pharmaceutical company’s stock after selling 3,220 shares during the period. Strategic Wealth Partners Ltd.’s holdings in GSK were worth $350,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nomura Holdings Inc. increased its holdings in GSK by 40.0% in the 4th quarter. Nomura Holdings Inc. now owns 118,834 shares of the pharmaceutical company’s stock worth $4,404,000 after acquiring an additional 33,979 shares in the last quarter. Barometer Capital Management Inc. bought a new stake in shares of GSK during the 4th quarter valued at $119,000. LM Advisors LLC purchased a new position in shares of GSK during the 4th quarter valued at $384,000. Clear Street Markets LLC boosted its holdings in GSK by 12.4% in the 4th quarter. Clear Street Markets LLC now owns 51,836 shares of the pharmaceutical company’s stock worth $1,921,000 after buying an additional 5,729 shares during the period. Finally, Cantor Fitzgerald L. P. increased its stake in GSK by 7,625.4% in the 4th quarter. Cantor Fitzgerald L. P. now owns 638,657 shares of the pharmaceutical company’s stock worth $23,669,000 after buying an additional 630,390 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 5.8 %

GSK stock opened at $40.24 on Thursday. The firm has a fifty day moving average price of $41.51 and a 200 day moving average price of $41.44. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The firm has a market cap of $83.40 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 1.31 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. Sell-side analysts anticipate that GSK plc will post 4.17 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a $0.3843 dividend. This represents a $1.54 annualized dividend and a dividend yield of 3.82%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 54.71%.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GSK. Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.